Cancer procoagulant inhibitors: New drugs for an old target.

The article presents the discussion on considering cancer procoagulant (CP) as diagnostic and therapeutic target in clinical oncology or oncology pharmacy. Topics include neoplastic cells in bloodstream inducing the platelet activation and triggering the coagulation cascade through the expression and releasing of the well-known thrombus forming factors; and anticoagulants with chemotherapeutic activity, chemotherapies with anti-coagulating properties, and natural products.